Sandoz wins UK bid to invalidate Biogen’s brain infection risk-assessment method patent
US drugmaker Biogen’s patented method for assessing the risk that multiple sclerosis patients will develop progressive multifocal leukoencephalopathy was declared invalid by the UK High Court. Biogen claimed Sandoz challenged the...To view the full article, register now.
Already a subscriber? Click here to view full article